Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma. The gene discussed is IBTK; the disease is diffuse large B-cell lymphoma.